1. Pink Sheet
  2. >>Geography
  3. >>Europe

European HTAs And Payers On How To Tackle The Evidence Problem

 
• By Francesca Bruce

European payers and health technology appraisal organizations have warned that their decision making is being increasingly hampered by evidence gaps. Some solutions may lie in the better use of existing mechanisms, such as scientific advice and managed entry agreements, while others could be introduced through the overhaul of the EU pharmaceutical legislation.

Arrow
Payers and HTAs explain how EU legislation change should move forward • Source: Alamy

European payer organizations and health technology appraisal (HTA) bodies have warned that the European Commission’s overhaul of the EU pharmaceutical legislation should not lead to faster marketing approval mechanisms. This would exacerbate existing problems for pricing and reimbursement decision makers caused by an increasing trend for regulatory approvals based on limited evidence, said speakers at a recent online event.

The solutions to the “uncertainty problem” could lie in greater collaboration between payers, HTAs and regulators at an earlier stage...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Belgium Competition Authority Tackles Reimbursement Barriers For Combination Drugs

 
• By Francesca Bruce

The Belgian Competition Authority has set out guidance on how pharmaceutical companies can share information on combination therapies when seeking their reimbursement.

EMA Backs 14 New Drugs, Confirms Atropine Rejection For Myopia

 
• By Vibha Sharma

The European Medicines Agency’s human medicines committee has recommended 14 new drugs for marketing approval, including treatments for RSV, menopause, diabetes, and generalized myasthenia gravis.

Speed, Reach And Impact: New Metrics To Drive EU Clinical Trials Reform

 
• By Vibha Sharma

Clinical trials in the EU will be measured against new benchmarks from 2026 to identify how the bloc’s clinical research environment compares with that of other regions, and to identify areas for improvement.

EU-Level Efforts To Mitigate Drug Shortages Unsuccessful, Audit Reveals

 
• By Eliza Slawther

Actions taken by the European Commission and European Medicines Agency to tackle critical shortages of medicines have not succeeded in practice and further systemic improvements are required to address supply issues, a report from the European Court of Auditors has found.

More from Geography

ACIP Weakened COVID-19 Vaccine Advice, But Less Than Rhetoric May Suggest

 
• By Sarah Karlin-Smith

The new recommendations should not change insurance coverage, but the tone of the meeting frustrated many medical experts, because of the negative comments on the vaccines.

Inexperience And Confusion: ACIP Struggles To End MMRV, Hep B Debates

 
• By Bridget Silverman

Confusion, inconsistency and strongly held views complicated the CDC's Advisory Committee on Immunization Practices' votes to change vaccine recommendations for the measles, mumps, rubella, varicella vaccine in young children and tabling of a vote on hepatitis B vaccine at birth.

US FDA Appears To Be Managing MAHA Well By Feeding Instead Of Receiving Priorities

 
• By Ramsey Baghdadi

The newly issued Make America Healthy Again strategy report suggests that FDA leaders are doing a good job of feeding ideas to the Trump Administration, rather than having the agency agenda dictated from above.